trastuzumab emtansine	standard therapy
Progression-free survival, mo	9.6	6.4
	HR: 0.65; p<0.001
Overall survival, mo	29.9	25.9
	HR: 0.75; p<0.001
Response rate, %	43.6	30.8
	p<0.001